<DOC>
	<DOCNO>NCT01325701</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ibrutinib ( PCI-32765 ) relapsed/refractory de novo activate B-cell ( ABC ) germinal-cell B-Cell ( GCB ) Diffuse Large B-cell Lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>Safety Efficacy Study BTK Inhibitor Subjects With Relapsed Refractory Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>The primary objective study evaluate efficacy ibrutinib administer 560 mg per day relapse refractory de novo ABC GCB DLBCL , evaluate efficacy ibrutinib administer 840 mg per day relapse refractory de novo ABC DLBCL . The secondary objective evaluate safety tolerability fix daily oral dose regimen ibrutinib relapsed/refractory de novo DLBCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Men woman ≥ 18 year age . 2 . ECOG performance status ≤ 2 . 3 . Pathologically confirm de novo DLBCL 4 . Subjects must available tissue central pathology review eligible . Treatment Group 2 : Subjects eligible nonGCB phenotype , confirmed Central IHC test Hans method . 5 . Relapsed refractory disease , define either : 1 ) recurrence disease CR , 2 ) PR , SD , progressive disease ( PD ) completion treatment regimen precede entry study ( residual disease ) : Subjects must previously receive appropriate firstline treatment regimen . Subjects receive HDT/ASCT must ineligible HDT/ASCT 6 . Treatment Group 1 : Subjects must ≥ 1 measurable ( &gt; 2 cm long dimension ) disease sit CT scan . Treatment Group 2 : Subjects must ≥ 1 measurable ( &gt; 1.5 cm long dimension ) disease sit CT scan . 1 . Transformed DLBCL DLBCL coexistent histology ( eg , FL MALT ) . 2 . Primary mediastinal ( thymic ) large Bcell lymphoma . 3 . Known central nervous system lymphoma . In addition , subject Treatment Group 2 , know leptomeningeal involvement exclusionary . 4 . Certain exclusion prior therapy 5 . Major surgery within 2 week first dose study drug . 6 . Any following laboratory abnormality : 1 . ANC &lt; 0.75 x 10^9/L . Treatment Group 2 : Eligible subject must independent growth factor support 7 day prior screen lab test . 2 . Platelet count &lt; 50 x 10^9/L independent transfusion support . Treatment Group 2 : Eligible subject must independent transfusion support 7 day prior screen lab test . 3 . AST ALT ≥ 3.0 x upper limit normal ( ULN ) 4 . Creatinine &gt; 2.0 x ULN 5 . Treatment Group 2 : Hemoglobin &lt; 8.0 g/dL 6 . Treatment Group 2 : Total Bilirubin &gt; 1.5 x ULN 7 . Requires receive anticoagulation treatment warfarin equivalent Vitamin K antagonist ( eg , phenprocoumon ) 8 . Treatment Group 2 : Requires treatment strong cytochrome P450 ( CYP ) 3A4/5 inhibitor 9 . Treatment Group 2 : Known bleed diathesis , eg , von Willebrand 's disease , hemophilia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PCI-32765</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Bruton 's Tyrosine Kinase</keyword>
	<keyword>Non Hodgkin 's Lymphoma</keyword>
	<keyword>Germinal Center B-Cell</keyword>
	<keyword>Activated B-Cell</keyword>
</DOC>